12,584 Eli Lilly and Company $LLY Shares Purchased by Kestra Advisory Services LLC

Key Points

• Kestra Advisory Services increased its Eli Lilly stake by 10.6% in the third quarter, purchasing 12,584 shares and bringing its holdings to 130,765 shares, valued at about $151.3 million.
• Eli Lilly reported quarterly earnings of $7.48 per share, beating the $5.71 analyst consensus, while revenue of $24.40 billion rose 38.6% year over year.
• Analysts’ consensus rating was Moderate Buy, with an average price target of $1,404.14; the company also declared a quarterly dividend of $1.73 per share.

Kestra Advisory Services LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 130,765 shares of the company's stock after buying an additional 12,584 shares during the quarter. Kestra Advisory Services LLC's holdings in Eli Lilly and Company were worth $151,306,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Integrity Financial Corp WA boosted its stake in shares of Eli Lilly and Company by 1.3% during the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock worth $767,000 after acquiring an additional 8 shares in the last quarter. LCM Capital Management Inc grew its holdings in shares of Eli Lilly and Company by 3.3% in the 3rd quarter. LCM Capital Management Inc now owns 253 shares of the company's stock worth $293,000 after acquiring an additional 8 shares during the period. Smith Shellnut Wilson LLC ADV increased its stake in Eli Lilly and Company by 4.1% in the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company's stock valued at $235,000 after purchasing an additional 8 shares in the last quarter. Financial Network Wealth Advisors LLC increased its stake in Eli Lilly and Company by 5.6% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company's stock valued at $175,000 after purchasing an additional 8 shares in the last quarter. Finally, Eads & Heald Wealth Management raised its holdings in Eli Lilly and Company by 0.5% during the third quarter. Eads & Heald Wealth Management now owns 1,469 shares of the company's stock worth $1,700,000 after purchasing an additional 8 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

LLY stock traded up $7.42 on Friday, reaching $1,372.15. The company had a trading volume of 3,802,992 shares, compared to its average volume of 2,624,130. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company's fifty day moving average is $1,215.24 and its 200 day moving average is $1,101.16. The company has a market cap of $1.29 trillion, a P/E ratio of 44.54, a PEG ratio of 1.77 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. Eli Lilly and Company's quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $7.02 EPS. On average, research analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.

Analyst Upgrades and Downgrades

A number of analysts have commented on LLY shares. Bank of America reiterated a "buy" rating and set a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. Truist Financial restated a "buy" rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. HSBC lifted their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday, September 10th. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Finally, TD Cowen reissued a "buy" rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,404.14.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company's stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $17,020,770 over the last quarter. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.